Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
jack.tan@rdm.ox.ac.uk

Website
https://scholar.google.com/citations?user=Vw-0vnIAAAAJ&hl=en

ORCID
https://orcid.org/0000-0001-8746-8308

Colleges

St Edmund Hall

Jack Tan

DPhil, BSc (Hons)

RDM Principal Investigator

Dr Tan is a Principal Investigator at the MRC Translational Immune Discovery Unit.

His research focuses developing next-generation protein nanoparticle-based vaccines and antibody therapeutics against infectious diseases. He is particularly interested in understanding how the architecture of protein nanoparticle vaccines influences their immunogenicity, as well as investigating mucosal vaccine immunity to improve vaccine design against respiratory pathogens such as coronavirus.

Dr Tan is part of an international consortium (Oxford-Caltech-CPI-Ingenza) funded by the Coalition of Epidemics Preparedness Innovations (CEPI) to develop novel a pan-sarbecovirus (SARS-like betacoronavirus) nanoparticle vaccine. He is also a Career Development Fellow at the Chinese-Academy of Medical Sciences-Oxford Institute, and a Fellow by Special Election at St Edmund Hall.

Recent publications

Molecular-level observation of the self-assembly of a virus-like particle

Asor R. et al, (2026)

Development of a Recombinant Single-Cycle Influenza Viral Vector as an Intranasal Vaccine against SARS-CoV-2 and SARS-like Betacoronaviruses.

Munro J. et al, (2025)

Translocating shRNA: a novel approach to RNA interference with Newcastle disease virus as viral vector.

Koh WC. et al, (2025), J Gen Virol, 106

Changes in Population Immunity to Omicron SARS-CoV-2 Variants and Selected Sarbecoviruses From 2020 to 2023 in Urban Colombo, Sri Lanka.

Bary F. et al, (2025), J Med Virol, 97

Determination of resilience of a panel of broadly neutralizing mAbs to emerging variants of SARS-CoV-2 generated using reverse genetics.

Afzal M. et al, (2025), iScience, 28

Publisher Correction: The molecular reach of antibodies crucially underpins their viral neutralisation capacity.

Huhn A. et al, (2025), Nat Commun, 16

A locally administered single-cycle influenza vaccine expressing a non-fusogenic stabilized hemagglutinin stimulates strong T-cell and neutralizing antibody immunity.

Sadler HL. et al, (2025), J Virol, 99

Development of a recombinant non-replicating Newcastle disease virus.

Cheow P-S. et al, (2025), Avian Pathol, 54, 149 - 157

The magnitude and cross reactivity of SARS-CoV-2 specific antibody responses in Sri Lankan children and association with the nutritional status

Jeewandara C. et al, (2025)

Single-cycle, pseudotyped reporter influenza virus to facilitate evaluation of treatment strategies for avian influenza, Ebola and other highly infectious diseases in vivo.

Tan TK. et al, (2025), Front Immunol, 16

The molecular reach of antibodies crucially underpins their viral neutralisation capacity

DUSHEK O., (2024), Nature Communications

Changes in population immunity to omicron SARS-CoV-2 variants and selected Sarbecoviruses from 2020 to 2023 in urban Colombo, Sri Lanka

Bary F. et al, (2024)

Proactive vaccination using multiviral Quartet Nanocages to elicit broad anti-coronavirus responses.

Hills RA. et al, (2024), Nat Nanotechnol, 19, 1216 - 1223

The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine.

Chen X. et al, (2024), PLoS Pathog, 20

A locally administered single cycle influenza vaccine expressing a non-fusogenic stabilised haemagglutinin stimulates strong T-cell and neutralising antibody immunity

Sadler HL. et al, (2024)

The magnitude and cross reactivity of SARS-CoV-2 specific antibody responses in vaccinated and unvaccinated Sri Lankan children and association with nutrition status

Jeewandara C. et al, (2023)

Single-cycle influenza virus vaccine generates lung CD8+ Trm that cross-react against viral variants and subvert virus escape mutants.

Zheng MZM. et al, (2023), Sci Adv, 9

Analysis of emergent bivalent antibody binding identifies the molecular reach as a critical determinant of SARS-CoV-2 neutralisation potency

Huhn A. et al, (2023)

Broadly neutralizing aptamers to SARS-CoV-2: A diverse panel of modified DNA antiviral agents.

Gelinas AD. et al, (2023), Mol Ther Nucleic Acids, 31, 370 - 382

Multiviral Quartet Nanocages Elicit Broad Anti-Coronavirus Responses for Proactive Vaccinology.

Hills RA. et al, (2023), bioRxiv